Deal Announcement Archives | Page 2 of 8

News | Deal Announcement

Leerink Partners Serves as Exclusive Financial Advisor and Placement Agent to Universal DX on its $70 Million Series B Financing and Strategic Collaboration with Quest Diagnostics

December 2023

News | Deal Announcement

Leerink Partners Serves as Exclusive Financial Advisor to Freeline Therapeutics (Nasdaq: FRLN) on its Going-Private Transaction with Syncona (LON: SYNC)

November 2023

News | Deal Announcement

Leerink Partners Serves as Exclusive Financial Advisor and Placement Agent for Q32 Bio’s Proposed Merger with Homology Medicines (Nasdaq: FIXX) and Concurrent $42 Million Private Placement

November 2023

News | Deal Announcement

Leerink Partners Serves as Exclusive Financial Advisor for Graphite Bio’s (Nasdaq: GRPH) Proposed Merger with LENZ Therapeutics

November 2023

News | Deal Announcement

Leerink Partners Serves as Joint Bookrunner for Celldex Therapeutics’ (Nasdaq: CLDX) $200 Million Follow-on Offering

November 2023

News | Deal Announcement

Leerink Partners Serves as Joint Bookrunner for Alpine Immune Sciences’ (Nasdaq: ALPN) $150 Million Follow-On Offering

November 2023

News | Deal Announcement

Leerink Partners Serves as Lead-Left Bookrunner for Aura Biosciences’ (Nasdaq: AURA) $99 Million Follow-on Offering

November 2023

News | Deal Announcement

Leerink Partners Serves as Joint Bookrunner for Lexeo Therapeutics’ (Nasdaq: LXEO) $100 Million Initial Public Offering

November 2023

News | Deal Announcement

Leerink Partners Serves as Global Coordinator and Joint Bookrunner for Nanobiotix’s (Nasdaq: NBTX) $30 Million Follow-on Offering

November 2023

News | Deal Announcement

Leerink Partners Serves as Joint Global Coordinator and Bookrunner for Abivax’s (Nasdaq: ABVX) $236 Million U.S. Initial Public Offering

October 2023

News | Deal Announcement

Leerink Partners Serves as Joint Bookrunner for Biohaven’s (NYSE: BHVN) $225 Million Follow-On Offering

October 2023

News | Deal Announcement

Leerink Partners Serves as Joint Placement Agent for Structure Therapeutics’ (Nasdaq: GPCR) $300 Million Private Investment in Public Equity (PIPE)

October 2023

Leerink Partners Serves as Exclusive Financial Advisor and Placement Agent to Universal DX on its $70 Million Series B Financing and Strategic Collaboration with Quest Diagnostics

Leerink Partners Serves as Exclusive Financial Advisor to Freeline Therapeutics (Nasdaq: FRLN) on its Going-Private Transaction with Syncona (LON: SYNC)

Leerink Partners Serves as Exclusive Financial Advisor and Placement Agent for Q32 Bio’s Proposed Merger with Homology Medicines (Nasdaq: FIXX) and Concurrent $42 Million Private Placement

Leerink Partners Serves as Exclusive Financial Advisor for Graphite Bio’s (Nasdaq: GRPH) Proposed Merger with LENZ Therapeutics

Leerink Partners Serves as Joint Bookrunner for Celldex Therapeutics’ (Nasdaq: CLDX) $200 Million Follow-on Offering

Leerink Partners Serves as Joint Bookrunner for Alpine Immune Sciences’ (Nasdaq: ALPN) $150 Million Follow-On Offering

Leerink Partners Serves as Lead-Left Bookrunner for Aura Biosciences’ (Nasdaq: AURA) $99 Million Follow-on Offering

Leerink Partners Serves as Joint Bookrunner for Lexeo Therapeutics’ (Nasdaq: LXEO) $100 Million Initial Public Offering

Leerink Partners Serves as Global Coordinator and Joint Bookrunner for Nanobiotix’s (Nasdaq: NBTX) $30 Million Follow-on Offering

Leerink Partners Serves as Joint Global Coordinator and Bookrunner for Abivax’s (Nasdaq: ABVX) $236 Million U.S. Initial Public Offering

Leerink Partners Serves as Joint Bookrunner for Biohaven’s (NYSE: BHVN) $225 Million Follow-On Offering

Leerink Partners Serves as Joint Placement Agent for Structure Therapeutics’ (Nasdaq: GPCR) $300 Million Private Investment in Public Equity (PIPE)

Sectors

Solutions

Intelligence

Firm

Contact

Stay ahead of what’s next. Sign Up Now!

Deal Announcement

Partner with Us

Footer

Sectors

Solutions

Intelligence

Firm

Contact

Stay ahead of what’s next. Sign Up Now!